Terran Biosciences, a biotech platform company dedicated to developing transformational therapeutics for neurological and psychiatric diseases, will acquire the portfolio of Concert’s CNS therapeutics accompanying intellectual property.

These deuterated compounds represent next-generation therapeutics with applications across several different psychiatric and neurological conditions. Terran plans to quickly accelerate the development of these compounds as important complements to a growing pipeline of both early-stage and late-stage therapeutics and technologies in the CNS space.

"It is Terran's goal to become an industry leader in neuropsychiatry by providing a suite of solutions for patients suffering from these diseases, which have not had many, if any, therapeutic options historically. With this acquisition from Concert, we get even closer to our goal," stated Dr. Sam Clark, Chief Executive Officer at Terran. 

These new chemical entities are covered by composition of matter patent applications. Financial terms of the deal were not disclosed.